Sugi Predict

Sugi Predict / Compounds / SCHEMBL12822253

SCHEMBL12822253

SCHEMBL12822253

O=C(c1ccc(Cn2c(=O)[nH]c(=O)c3ccccc32)cc1)N1CCN(c2ncccn2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK10 P53779 4/20 0.60
▸ HSD17B10 Q99714 3/20 0.60
▸ SMN1; SMN2 Q16637 4/20 0.55
▸ LMNA P02545 4/20 0.55
▸ HPGD P15428 4/20 0.55
▸ NPSR1 Q6W5P4 3/20 0.55
▸ USP2 O75604 2/20 0.55
▸ HTT P42858 3/20 0.54
▸ ALDH1A1 P00352 4/20 0.54
▸ MGLL Q99685 1/20 0.54
▸ TNF P01375 1/20 0.54
▸ NOD2 Q9HC29 1/20 0.54
▸ NOD1 Q9Y239 1/20 0.54
▸ SLC6A7 Q99884 6/20 0.53
▸ MAPT P10636 2/20 0.52
▸ TSHR P16473 1/20 0.52
▸ PARP1 P09874 3/20 0.52
▸ PTGS1 P23219 2/20 0.52
▸ PTGS2 P35354 2/20 0.52
▸ KDM4E B2RXH2 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12822321 0.90 MAPK10 (0.74) MAPK10HSD17B10SMN1; SMN2LMNAHPGD
SCHEMBL30418027 0.90 PARP1 (0.61) MAPK10HSD17B10HPGDALDH1A1MGLL
SCHEMBL12821925 0.90 PARP1 (0.61) MAPK10HSD17B10HPGDALDH1A1MGLL
Hydrochloric Acid SCHEMBL15420661 0.90 PARP1 (0.61) MAPK10HSD17B10HPGDALDH1A1MGLL
SCHEMBL12822343 0.88 LMNA (0.60) MAPK10HSD17B10SMN1; SMN2LMNAHPGD
SCHEMBL30427941 0.88 LMNA (0.60) MAPK10HSD17B10SMN1; SMN2LMNAHPGD
SCHEMBL15420842 0.87 PARP1 (0.51) MAPK10HSD17B10HPGDALDH1A1PARP1
SCHEMBL15421190 0.87 PARP1 (0.57) PARP1PARP2
SCHEMBL15420791 0.87 LMNA (0.50) MAPK10HSD17B10SMN1; SMN2LMNAHPGD
SCHEMBL12700100 0.86 PARP1 (0.51) HPGDALDH1A1PARP1PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230263801-A1 COMBINATION THERAPY OF PARP INHIBITORS Impact Therapeutics (Shanghai), Inc (CN) 2023-08-24 — — US claimed
US-20230263801-A1 COMBINATION THERAPY OF PARP INHIBITORS Impact Therapeutics (Shanghai), Inc (CN) 2023-08-24 — — US disclosed
US-11358955-B2 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof IMPACT THERAPEUTICS, INC. (CN) 2022-06-14 — — US disclosed
US-20190270732-A1 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof IMPACT THERAPEUTICS, INC. (CN) 2019-09-05 — — US disclosed
EP-2709990-B1 1-((3-((1-Piperazinyl)carbonyl)phenyl)methyl)-2,4(1H,3H)-quinazolinedione derivatives as PARP inhibitors for treating cancer IMPACT THERAPEUTICS INC (CN) 2019-06-12 — — EP disclosed
US-10316027-B2 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof IMPACT THERAPEUTICS, INC. (CN) 2019-06-11 — — US disclosed
US-20180215741-A1 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof IMPACT THERAPEUTICS INC (CN) 2018-08-02 — — US disclosed
US-9926304-B2 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof IMPACT THERAPEUTICS, INC. (CN) 2018-03-27 — — US disclosed
US-20160237070-A1 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof IMPACT THERAPEUTICS, INC. (CN) 2016-08-18 — — US disclosed
US-9290460-B2 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof IMPACT THERAPEUTICS, INC. (CN) 2016-03-22 — — US disclosed
EP-2709990-A1 1-(ARYLMETHYL)QUINAZOLINE-2,4(1H,3H)-DIONES AS PARP INHIBITORS AND THE USE THEREOF Impact Therapeutics, Inc. (CN) 2014-03-26 — — EP disclosed
US-20140023642-A1 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof IMPACT THERAPEUTICS, INC. (CN) 2014-01-23 — — US disclosed
WO-2012130166-A1 1-(ARYLMETHYL)QUINAZOLINE-2,4(1H,3H)-DIONES AS PARP INHIBITORS AND THE USE THEREOF IMPACT THERAPEUTICS, INC. (CN) 2012-10-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190270732-A1 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof PARP1, PARP11, PARP3 MAPK10 2053/4885HSD17B10 2206/4885SMN1; SMN2 3276/4885
US-20230263801-A1 COMBINATION THERAPY OF PARP INHIBITORS PARP2, PARP1, PARP3 MAPK10 847/4885HSD17B10 2424/4885SMN1; SMN2 3622/4885
US-10316027-B2 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof PARP1, PARP11, PARP3 MAPK10 2026/4885HSD17B10 2345/4885SMN1; SMN2 3409/4885
US-20160237070-A1 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof PARP1, PARP11, PARP3 MAPK10 2053/4885HSD17B10 2206/4885SMN1; SMN2 3276/4885
US-20180215741-A1 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof PARP1, PARP11, PARP3 MAPK10 2026/4885HSD17B10 2345/4885SMN1; SMN2 3409/4885
US-11358955-B2 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof PARP1, PARP11, PARP3 MAPK10 2053/4885HSD17B10 2206/4885SMN1; SMN2 3276/4885
US-20140023642-A1 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof PARP1, PARP11, PARP3 MAPK10 2127/4885HSD17B10 2244/4885SMN1; SMN2 3511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.